David W Ellison

List of Publications by Year
in descending order

139 papers	35,659 citations	23544 58 h-index	13758 129 g-index
143 all docs	143 docs citations	143 times ranked	31339 citing authors

#	Article	IF	Citations
1	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica, 2016, 131, 803-820.	3.9	12,144
2	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology, 2021, 23, 1231-1251.	0.6	4,534
3	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	13.7	1,872
4	Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica, 2012, 123, 465-472.	3.9	1,536
5	Germline Mutations in Predisposition Genes in Pediatric Cancer. New England Journal of Medicine, 2015, 373, 2336-2346.	13.9	949
6	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell, 2015, 27, 728-743.	7.7	933
7	The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nature Genetics, 2014, 46, 444-450.	9.4	871
8	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	13.5	702
9	Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features. PLoS ONE, 2008, 3, e3088.	1.1	606
10	Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma. Cell Reports, 2014, 7, 104-112.	2.9	583
11	C11orf95â€“RELA fusions drive oncogenic NF-Î²B signalling in ependymoma. Nature, 2014, 506, 451-455.	13.7	559
12	<scp>I</scp>nternational <scp>S</scp>ociety of <scp>N</scp>europathologyâ€•<scp>H</scp>aarlem <scp>C</scp>onsensus <scp>G</scp>uidelines for <scp>N</scp>ervous <scp>S</scp>ystem <scp>T</scp>umor <scp>C</scp>lassification and <scp>G</scp>rading. Brain Pathology, 2014, 24, 429-435.	2.1	499
13	Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathologica, 2011, 121, 381-396.	3.9	474
14	Î²-Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. Journal of Clinical Oncology, 2005, 23, 7951-7957.	0.8	411
15	Medulloblastoma. Nature Reviews Disease Primers, 2019, 5, 11.	18.1	376
16	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	7.7	372
17	Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehogâ€“Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. Journal of Clinical Oncology, 2015, 33, 2646-2654.	0.8	368
18	The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nature Communications, 2014, 5, 3630.	5.8	342

#	Article	IF	Citations
19	Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathologica, 2016, 131, 833-845.	3.9	288
20	Survival and Prognostic Factors of Early Childhood Medulloblastoma: An International Meta-Analysis. Journal of Clinical Oncology, 2010, 28, 4961-4968.	0.8	273
21	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathologica, 2017, 133, 5-12.	3.9	271
22	Definition of Disease-Risk Stratification Groups in Childhood Medulloblastoma Using Combined Clinical, Pathologic, and Molecular Variables. Journal of Clinical Oncology, 2011, 29, 1400-1407.	0.8	263
23	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell, 2020, 37, 569-583.e5.	7.7	244
24	Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. Journal of Negative Results in BioMedicine, 2011, 10, 7.	1.4	239
25	Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathologica, 2018, 136, 211-226.	3.9	199
26	Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression. Cancer Cell, 2019, 35, 140-155.e7.	7.7	194
27	cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation. Acta Neuropathologica, 2019, 137, 683-687.	3.9	170
28	cIMPACTâ€NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathology, 2020, 30, 863-866.	2.1	168
29	Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. Cancer Cell, 2015, 27, 72-84.	7.7	165
30	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 2020, 10, 942-963.	7.7	157
31	Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. Journal of Clinical Oncology, 2019, 37, 974-983.	0.8	154
32	Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncology, The, 2018, 19, 768-784.	5.1	151
33	A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathologica, 2012, 123, 727-738.	3.9	148
34	The Genomic Landscape of Childhood and Adolescent Melanoma. Journal of Investigative Dermatology, 2015, 135, 816-823.	0.3	148
35	Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. Nature Communications, 2018, 9, 3962.	5.8	142
36	Multi-organ Mapping of Cancer Risk. Cell, 2016, 166, 1132-1146.e7.	13.5	128

#	Article	IF	Citations
37	Cancer-associated DDX3X mutations drive stress granule assembly and impair global translation. Scientific Reports, 2016, 6, 25996.	1.6	121
38	Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathologica, 2017, 133, 1-3.	3.9	120
39	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. Acta Neuropathologica, 2018, 136, 239-253.	3.9	118
40	Pediatric low-grade gliomas: next biologically driven steps. Neuro-Oncology, 2018, 20, 160-173.	0.6	116
41	Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children's Cancer Leukaemia Group (CCLG), SociÃ©tÃ© FranÃ§aise d'Oncologie PÃ©diatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Clinical Cancer Research, 2012, 18, 2001-2011.	3.2	111
42	St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem. Cancer Discovery, 2021, 11, 1082-1099.	7.7	109
43	Morphophenotypic Variation Predicts Clinical Behavior in Childhood Non-Desmoplastic Medulloblastomas. Journal of Neuropathology and Experimental Neurology, 2003, 62, 627-632.	0.9	107
44	Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathologica, 2010, 120, 305-316.	3.9	107
45	EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma. Neuro-Oncology, 2019, 21, 878-889.	0.6	106
46	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). Journal of Clinical Oncology, 2021, 39, 822-835.	0.8	106
47	Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathologica, 2012, 124, 247-257.	3.9	101
48	Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomasâ€”Same Entity or First Cousins?. Brain Pathology, 2016, 26, 215-223.	2.1	95
49	The molecular landscape of ETMR at diagnosis and relapse. Nature, 2019, 576, 274-280.	13.7	94
50	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. Nature, 2020, 580, 396-401.	13.7	94
51	Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing. Cancer Discovery, 2021, 11, 3008-3027.	7.7	88
52	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	3.9	86
53	H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. Acta Neuropathologica, 2019, 137, 637-655.	3.9	85
54	Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. Clinical Cancer Research, 2015, 21, 184-192.	3.2	84

#	Article	IF	Citations
55	Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. Acta Neuropathologica, 2020, 139, 193-209.	3.9	83
56	CICERO: a versatile method for detecting complex and diverse driver fusions using cancer RNA sequencing data. Genome Biology, 2020, 21, 126.	3.8	74
57	Pediatric low-grade gliomas: implications of the biologic era. Neuro-Oncology, 2017, 19, now209.	0.6	73
58	Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma. International Journal of Radiation Oncology Biology Physics, 2018, 100, 507-515.	0.4	71
59	CONSERTING: integrating copy-number analysis with structural-variation detection. Nature Methods, 2015, 12, 527-530.	9.0	68
60	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell, 2021, 39, 1519-1530.e4.	7.7	64
61	cIMPACTâ€NOW (the consortium to inform molecular and practical approaches to CNS tumor) Tj ETQq1 1 0.784314 rgBT /Overlock 10 27, 851-852.	2.1	63
62	Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial. Neuro-Oncology, 2019, 21, 1319-1330.	0.6	63
63	Structure and evolution of double minutes in diagnosis and relapse brain tumors. Acta Neuropathologica, 2019, 137, 123-137.	3.9	63
64	An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes. Nature Genetics, 2015, 47, 878-887.	9.4	62
65	Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas. Nature Medicine, 2019, 25, 597-602.	15.2	61
66	A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-ÎºB. Cell Reports, 2018, 23, 3787-3797.	2.9	53
67	Molecular pathology of paediatric central nervous system tumours. Journal of Pathology, 2017, 241, 159-172.	2.1	51
68	Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. Acta Neuropathologica, 2020, 139, 243-257.	3.9	50
69	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro-Oncology, 2021, 23, 1360-1370.	0.6	46
70	A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration. Acta Neuropathologica, 2019, 138, 1091-1092.	3.9	45
71	YAP1-fusions in pediatric NF2-wildtype meningioma. Acta Neuropathologica, 2020, 139, 215-218.	3.9	45
72	Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource. Acta Neuropathologica, 2020, 140, 209-225.	3.9	45

#	Article	IF	Citations
73	Subsequent neoplasms in survivors of childhood central nervous system tumors: risk after modern multimodal therapy. Neuro-Oncology, 2015, 17, 448-456.	0.6	44
74	Intracranial mesenchymal tumor with FETâ€CREB fusionâ€"A unifying diagnosis for the spectrum of intracranial myxoid mesenchymal tumors and angiomatoid fibrous histiocytomaâ€like neoplasms. Brain Pathology, 2021, 31, e12918.	2.1	44
75	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	0.8	40
76	Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro-Oncology, 2020, 22, 1474-1483.	0.6	39
77	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusionâ€"Positive Supratentorial Ependymomas. Cancer Discovery, 2021, 11, 2230-2247.	7.7	39
78	Septal dysembryoplastic neuroepithelial tumor: a comprehensive clinical, imaging, histopathologic, and molecular analysis. Neuro-Oncology, 2019, 21, 800-808.	0.6	38
79	Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISHÂand IHC in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 1891-1900.	0.5	37
80	Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. Acta Neuropathologica, 2020, 139, 259-271.	3.9	36
81	Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clinical Cancer Research, 2021, 27, 2879-2889.	3.2	35
82	Multiple Molecular Data Sets and the Classification of Adult Diffuse Gliomas. New England Journal of Medicine, 2015, 372, 2555-2557.	13.9	33
83	Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data. Neuro-Oncology, 2017, 19, now234.	0.6	33
84	Low-grade spinal glioneuronal tumors with BRAF gene fusion and 1p deletion but without leptomeningeal dissemination. Acta Neuropathologica, 2017, 134, 159-162.	3.9	33
85	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathologica, 2021, 142, 827-839.	3.9	33
86	Clinical, imaging, and molecular analysis of pediatric pontine tumors lacking characteristic imaging features of DIPG. Acta Neuropathologica Communications, 2020, 8, 57.	2.4	32
87	Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas. Frontiers in Oncology, 2014, 4, 67.	1.3	31
88	Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. Acta Neuropathologica, 2021, 141, 281-290.	3.9	31
89	Atypical teratoid/rhabdoid tumor with retained <scp>INI</scp>1 (<scp>SMARCB1</scp>) expression and loss of <scp>BRG</scp>1 (<scp>SMARCA4</scp>). Neuropathology, 2018, 38, 305-308.	0.7	26
90	Enrichment of heterozygous germline RECQL4 loss-of-function variants in pediatric osteosarcoma. Journal of Physical Education and Sports Management, 2019, 5, a004218.	0.5	26

#	Article	IF	Citations
91	Molecular Heterogeneity in a Patient-Derived Glioblastoma Xenoline Is Regulated by Different Cancer Stem Cell Populations. PLoS ONE, 2015, 10, e0125838.	1.1	25
92	Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia Caused by a Novel R782G Mutation in CSF1R. Scientific Reports, 2015, 5, 10042.	1.6	22
93	Case Report of Spontaneous Resolution of a Congenital Glioblastoma. Pediatrics, 2016, 137, .	1.0	20
94	Quantitative imaging analysis of posterior fossa ependymoma location in children. Child's Nervous System, 2016, 32, 1441-1447.	0.6	20
95	PTEN Signaling in the Postnatal Perivascular Progenitor Niche Drives Medulloblastoma Formation. Cancer Research, 2017, 77, 123-133.	0.4	20
96	Clinicopathologic and molecular features of intracranial desmoplastic small round cell tumors. Brain Pathology, 2020, 30, 213-225.	2.1	20
97	DNA methylation analysis of paediatric low-grade astrocytomas identifies a tumour-specific hypomethylation signature in pilocytic astrocytomas. Acta Neuropathologica Communications, 2016, 4, 54.	2.4	17
98	Surgical and molecular considerations in the treatment of pediatric thalamopeduncular tumors. Journal of Neurosurgery: Pediatrics, 2017, 20, 247-255.	0.8	16
99	Miniâ€symposium in medulloblastoma genomics in the modern molecular era. Brain Pathology, 2020, 30, 661-663.	2.1	16
100	Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile. Modern Pathology, 2021, 34, 264-279.	2.9	16
101	SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohortâ€"A BIOMECA Consortium Study. Neuro-Oncology, 2022, 24, 936-948.	0.6	16
102	Dedifferentiation in SDH-Deficient Gastrointestinal Stromal Tumor: A Report With Histologic, Immunophenotypic, and Molecular Characterization. Pediatric and Developmental Pathology, 2019, 22, 492-498.	0.5	15
103	Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma. Cancer Research, 2019, 79, 2208-2219.	0.4	15
104	Clear cell sarcoma of kidney involving a horseshoe kidney and harboring EGFR internal tandem duplication. Pediatric Blood and Cancer, 2017, 64, e26602.	0.8	14
105	Tectal glioma harbors high rates of KRAS G12R and concomitant KRAS and BRAF alterations. Acta Neuropathologica, 2020, 139, 601-602.	3.9	13
106	Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026). Neuro-Oncology, 2022, 24, 1178-1190.	0.6	13
107	Risk stratification in pediatric low-grade glioma and glioneuronal tumor treated with radiation therapy: an integrated clinicopathologic and molecular analysis. Neuro-Oncology, 2020, 22, 1203-1213.	0.6	12
108	Intracranial mesenchymal tumors with FETâ€CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomas. Brain Pathology, 2022, 32, e13037.	2.1	11

#	Article	IF	Citations
109	Pediatric Posterior Fossa Medulloblastoma: The Role of Diffusion Imaging in Identifying Molecular Groups. Journal of Neuroimaging, 2020, 30, 503-511.	1.0	9
110	Incidence of Germline Mutations in Cancer-Predisposition Genes in Children with Hematologic Malignancies: a Report from the Pediatric Cancer Genome Project. Blood, 2014, 124, 127-127.	0.6	9
111	Anatomic Neuroimaging Characteristics of Posterior Fossa Type A Ependymoma Subgroups. American Journal of Neuroradiology, 2021, 42, 2245-2250.	1.2	9
112	A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B).. Journal of Clinical Oncology, 2013, 31, 2035-2035.	0.8	8
113	Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study. Clinical Cancer Research, 2022, 28, 116-128.	3.2	8
114	The landscape of coding RNA editing events in pediatric cancer. BMC Cancer, 2021, 21, 1233.	1.1	7
115	Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. Neuro-Oncology, 0, , .	0.6	7
116	Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations. Pediatric Blood and Cancer, 2015, 62, 1855-1858.	0.8	6
117	Outcome and molecular analysis of young children with choroid plexus carcinoma treated with non-myeloablative therapy: results from the SJYC07 trial. Neuro-Oncology Advances, 2021, 3, vdaa168.	0.4	6
118	A rare variant analysis framework using public genotype summary counts to prioritize disease-predisposition genes. Nature Communications, 2022, 13, 2592.	5.8	6
119	Diffuse Midline Glioma With Osseous Metastases at Diagnosis: A Case Report. Journal of Pediatric Hematology/Oncology, 2020, 42, e673-e676.	0.3	5
120	The molecular characteristics of lowâ€grade and highâ€grade areas in desmoplastic infantile astrocytoma/ganglioglioma. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	5
121	Relative ADC and Location Differ between Posterior Fossa Pilocytic Astrocytomas with and without Gangliocytic Differentiation. American Journal of Neuroradiology, 2016, 37, 2370-2375.	1.2	4
122	From uncertainty to pathogenicity: clinical and functional interrogation of a rare TP53 in-frame deletion. Journal of Physical Education and Sports Management, 2019, 5, a003921.	0.5	4
123	Phase II study of alisertib as a single agent in recurrent or progressive atypical teratoid rhabdoid tumors.. Journal of Clinical Oncology, 2020, 38, 10542-10542.	0.8	4
124	Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. Neuro-Oncology, 2022, 24, 1166-1175.	0.6	2
125	C11ORF95-RELA FUSIONS DRIVE ONCOGENIC NF-KB SIGNALING IN EPENDYMOMA. Neuro-Oncology, 2014, 16, iii16-iii16.	0.6	1
126	Outcomes for young children with molecularly defined ependymoma treated on the multi-institutional SJYC07 clinical trial.. Journal of Clinical Oncology, 2018, 36, 10548-10548.	0.8	1

#	Article	IF	Citations
127	ATRT-22. Outcomes for children with recurrent atypical teratoid rhabdoid tumor: A single institution study with updated molecular and germline analysis. Neuro-Oncology, 2022, 24, i8-i8.	0.6	1
128	MPTH-26MOLECULAR REFINEMENT OF PEDIATRIC POSTERIOR FOSSA EPENDYMOMA. Neuro-Oncology, 2015, 17, v144.1-v144.	0.6	0
129	PNR-08NEWLY DISCOVERED ONCOGENES DRIVING AND MAINTAINING CHOROID PLEXUS CARCINOMA PROVIDE POTENTIALLY DRUGGABLE TARGETS. Neuro-Oncology, 2016, 18, iii8.2-iii8.	0.6	0
130	A 4â€Yearâ€Old Girl With a Supratentorial Mass. Brain Pathology, 2020, 30, 421-422.	2.1	0
131	Abstract 642: Genomes for Kids: Comprehensive DNA and RNA sequencing defining the scope of actionable mutations in pediatric cancer. , 2021, , .		0
132	Use of whole genome sequencing to identify novel mutations in distinct subgroups of medulloblastoma.. Journal of Clinical Oncology, 2012, 30, 9518-9518.	0.8	0
133	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Blood, 2015, 126, 481-481.	0.6	0
134	Prevalence of RNA Editing Events Affecting Coding Regions in Pediatric Leukemia. Blood, 2016, 128, 3928-3928.	0.6	0
135	OR02-1 DNA Methylation Profiling in Pediatric Adrenocortical Tumors Reveals Distinct Methylation Signatures with Prognostic Significance: A Report from the International Pediatric Adrenocortical Tumor Registry. Journal of the Endocrine Society, 2019, 3, .	0.1	0
136	Real-time sharing of comprehensive clinical genomics sequencing data in St. Jude Cloud.. Journal of Clinical Oncology, 2019, 37, 10019-10019.	0.8	0
137	BIOM-36. SERIAL ASSESSMENT OF MEASURABLE RESIDUAL DISEASE IN MEDULLOBLASTOMA LIQUID BIOPSIES. Neuro-Oncology, 2021, 23, vi18-vi19.	0.6	0
138	Phase II Study of Intravenous Etoposide in Patients with Relapsed Ependymoma (CNS 2001 04). Neuro-Oncology Advances, 2022, 4, vdac053.	0.4	0
139	PATH-03. Clinically Tractable Outcome Prediction of Group 3/4 Medulloblastoma Based on TPD52 Immunohistochemistry: a Multicohort Study. Neuro-Oncology, 2022, 24, i158-i158.	0.6	0